Akebia Therapeutics (AKBA) Net Cash Flow Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Net Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -236.85% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -1,020.00% |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn | -136.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -136.08% |
| Dec 31, 2025 | 3.06% |
| Sep 30, 2025 | 632.35% |
| Jun 30, 2025 | 1,075.11% |
| Mar 31, 2025 | 6,527.27% |
| Dec 31, 2024 | 596.30% |
| Sep 30, 2024 | 23.09% |
| Jun 30, 2024 | 43.83% |
| Mar 31, 2024 | 97.14% |
| Dec 31, 2023 | 93.42% |
| Sep 30, 2023 | -919.93% |
| Jun 30, 2023 | 85.75% |
| Mar 31, 2023 | -229.81% |
| Dec 31, 2022 | 4.75% |
| Sep 30, 2022 | 102.18% |
| Jun 30, 2022 | -431.34% |
| Mar 31, 2022 | 9.04% |
| Dec 31, 2021 | -196.62% |
| Sep 30, 2021 | 47.73% |
| Jun 30, 2021 | -104.44% |